Literature DB >> 17620367

Osteopontin gene expression determines spontaneous metastatic performance of orthotopic human breast cancer xenografts.

Mika Suzuki1, Evangeline Mose, Christine Galloy, David Tarin.   

Abstract

A major problem in the therapeutic management of cancer is the growth of metastases in distant organs, but the genes orchestrating the process need to be identified for the rational design of new treatment. Here, we provide decisive experimental evidence demonstrating the causal involvement of a specific gene, osteopontin (OPN), in the pathogenesis of metastasis by human breast cancer cells and implicating some of its probable partners. Stable long-term depletion, or up-regulation, of OPN gene expression in a matched, isogenic pair of human breast cancer cell lines of differing metastatic proficiency reproducibly changed their ability to colonize distant organs. OPN down-regulation was achieved by transduction of the metastatic line with a DNA construct encoding a small hairpin RNA in a vector labeled with red fluorescent protein and resulted in a marked reduction of metastatic load (P < 0.01). Up-regulation of OPN in the negligibly metastatic line, with a green fluorescent protein-marked retroviral vector containing OPN cDNA driven by a strong promoter, resulted in heavy colonization of the lungs and lymph nodes (P < 0.005). The reciprocal changes in behavior of these matched cell lines cross-corroborate each other. Concomitant changes were seen in the expression of other metastasis-related genes in both modulated lines. The data indicate that therapeutic targeting of tumor OPN molecules could reset metastatically relevant gene networks, resulting in clinical benefit.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17620367      PMCID: PMC1934534          DOI: 10.2353/ajpath.2007.070232

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  46 in total

1.  Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer.

Authors:  Alison L Allan; Rosamma George; Sharon A Vantyghem; Mark W Lee; Nicole C Hodgson; C Jay Engel; Ron L Holliday; David P Girvan; Leslie A Scott; Carl O Postenka; Waleed Al-Katib; Larry W Stitt; Toshimitsu Uede; Ann F Chambers; Alan B Tuck
Journal:  Am J Pathol       Date:  2006-07       Impact factor: 4.307

2.  Serial plasma osteopontin levels have prognostic value in metastatic breast cancer.

Authors:  Vivien H C Bramwell; Gordon S Doig; Alan B Tuck; Sylvia M Wilson; Katia S Tonkin; Anna Tomiak; Francisco Perera; Theodore A Vandenberg; Ann F Chambers
Journal:  Clin Cancer Res       Date:  2006-06-01       Impact factor: 12.531

3.  Papilloma development is delayed in osteopontin-null mice: implicating an antiapoptosis role for osteopontin.

Authors:  Yu-Hua Hsieh; M Margaret Juliana; Patricia H Hicks; Gong Feng; Craig Elmets; Lucy Liaw; Pi-Ling Chang
Journal:  Cancer Res       Date:  2006-07-15       Impact factor: 12.701

4.  The osteoblast transcription factor Runx2 is expressed in mammary epithelial cells and mediates osteopontin expression.

Authors:  Claire K Inman; Paul Shore
Journal:  J Biol Chem       Date:  2003-09-23       Impact factor: 5.157

5.  Tumor-stromal interactions reciprocally modulate gene expression patterns during carcinogenesis and metastasis.

Authors:  Valérie Montel; Evangeline Sari Mose; David Tarin
Journal:  Int J Cancer       Date:  2006-07-15       Impact factor: 7.396

6.  An inducible short-hairpin RNA vector against osteopontin reduces metastatic potential of human esophageal squamous cell carcinoma in vitro and in vivo.

Authors:  Tetsuo Ito; Yosuke Hashimoto; Eiji Tanaka; Takatsugu Kan; Shigeru Tsunoda; Fumiaki Sato; Motoshige Higashiyama; Tomoyuki Okumura; Yutaka Shimada
Journal:  Clin Cancer Res       Date:  2006-02-15       Impact factor: 12.531

7.  Altered metastatic behavior of human breast cancer cells after experimental manipulation of matrix metalloproteinase 8 gene expression.

Authors:  Valerie Montel; Jeanine Kleeman; Dianne Agarwal; Dominic Spinella; Kanji Kawai; David Tarin
Journal:  Cancer Res       Date:  2004-03-01       Impact factor: 12.701

8.  Integrin-linked kinase regulates osteopontin-dependent MMP-2 and uPA expression to convey metastatic function in murine mammary epithelial cancer cells.

Authors:  Zhiyong Mi; Hongtao Guo; Philip Y Wai; Chengjiang Gao; Paul C Kuo
Journal:  Carcinogenesis       Date:  2006-02-12       Impact factor: 4.944

9.  Molecular analysis of metastasis in a polyomavirus middle T mouse model: the role of osteopontin.

Authors:  Katayoun Alavi Jessen; Stephenie Y Liu; Clifford G Tepper; Juliana Karrim; Erik T McGoldrick; Andrea Rosner; Robert J Munn; Lawrence J T Young; Alexander D Borowsky; Robert D Cardiff; Jeffrey P Gregg
Journal:  Breast Cancer Res       Date:  2004-02-25       Impact factor: 6.466

Review 10.  Role of osteopontin in tumour progression.

Authors:  S R Rittling; A F Chambers
Journal:  Br J Cancer       Date:  2004-05-17       Impact factor: 7.640

View more
  9 in total

1.  Anti-cancer activities of tea epigallocatechin-3-gallate in breast cancer patients under radiotherapy.

Authors:  G Zhang; Y Wang; Y Zhang; X Wan; J Li; K Liu; F Wang; K Liu; Q Liu; C Yang; P Yu; Y Huang; S Wang; P Jiang; Z Qu; J Luan; H Duan; L Zhang; A Hou; S Jin; T-C Hsieh; E Wu
Journal:  Curr Mol Med       Date:  2012-02       Impact factor: 2.222

2.  Effect of a 12-month exercise intervention on serum biomarkers of angiogenesis in postmenopausal women: a randomized controlled trial.

Authors:  Catherine Duggan; Liren Xiao; Ching-Yun Wang; Anne McTiernan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-02-05       Impact factor: 4.254

Review 3.  Osteopontin: an effector and an effect of tumor metastasis.

Authors:  L A Shevde; S Das; D W Clark; R S Samant
Journal:  Curr Mol Med       Date:  2010-02       Impact factor: 2.222

4.  Clinical and biological implications of the tumor microenvironment.

Authors:  David Tarin
Journal:  Cancer Microenviron       Date:  2012-08

5.  Growth of v-src-transformed cells in serum-free medium through the induction of growth factors.

Authors:  Tiziana Deangelis; Andrew Quong; Andrea Morrione; Renato Baserga
Journal:  J Cell Physiol       Date:  2013-07       Impact factor: 6.384

6.  Extracellular and intracellular mechanisms that mediate the metastatic activity of exogenous osteopontin.

Authors:  Jami Mandelin; Emme C K Lin; Dana D Hu; Susan K Knowles; Kim-Anh Do; Xuemei Wang; E Helene Sage; Jeffrey W Smith; Wadih Arap; Renata Pasqualini
Journal:  Cancer       Date:  2009-04-15       Impact factor: 6.860

Review 7.  Issues regarding improving the impact of antiangiogenic drugs for the treatment of breast cancer.

Authors:  Robert S Kerbel
Journal:  Breast       Date:  2009-10       Impact factor: 4.380

8.  Modulation of growth and angiogenic potential of oral squamous carcinoma cells in vitro using salvianolic acid B.

Authors:  Ya Yang; Ping J Ge; Long Jiang; Feng L Li; Qin Y Zhu
Journal:  BMC Complement Altern Med       Date:  2011-07-05       Impact factor: 3.659

9.  Osteopontin regulates proliferation, apoptosis, and migration of murine claudin-low mammary tumor cells.

Authors:  S Saleh; D E Thompson; J McConkey; P Murray; R A Moorehead
Journal:  BMC Cancer       Date:  2016-06-10       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.